|362.18||+14.23||+4.09%||Vol 815.55K||1Y Perf -32.84%|
|May 13th, 2022 16:00 DELAYED|
|- -%||- -|
|Target Price||612.17||Analyst Rating||Moderate Buy 1.81|
|Potential %||69.02||Finscreener Ranking||★+ 43.54|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 39.49|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 66.34|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||8.38||Earnings Rating||Strong Sell|
|Market Cap||30.43B||Earnings Date||4th May 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||2.25|
|EPS Growth Next 5 Years %||19.00|
|Avg. Weekly Volume||1.11M|
|Avg. Monthly Volume||831.28K|
|Avg. Quarterly Volume||605.60K|
IDEXX Laboratories Inc. (NASDAQ: IDXX) stock closed at 362.18 per share at the end of the most recent trading day (a 4.09% change compared to the prior day closing price) with a volume of 815.55K shares and market capitalization of 30.43B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 9300 people. IDEXX Laboratories Inc. CEO is Jonathan J. Mazelsky.
The one-year performance of IDEXX Laboratories Inc. stock is -32.84%, while year-to-date (YTD) performance is -45%. IDXX stock has a five-year performance of 121.9%. Its 52-week range is between 330.66 and 706.95, which gives IDXX stock a 52-week price range ratio of 8.38%
IDEXX Laboratories Inc. currently has a PE ratio of 43.00, a price-to-book (PB) ratio of 48.14, a price-to-sale (PS) ratio of 8.85, a price to cashflow ratio of 42.40, a PEG ratio of 2.32, a ROA of 30.67%, a ROC of 41.80% and a ROE of 112.72%. The company’s profit margin is 22.44%, its EBITDA margin is 31.70%, and its revenue ttm is $3.27 Billion , which makes it $38.98 revenue per share.
Of the last four earnings reports from IDEXX Laboratories Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.25 for the next earnings report. IDEXX Laboratories Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for IDEXX Laboratories Inc. is Moderate Buy (1.81), with a target price of $612.17, which is +69.02% compared to the current price. The earnings rating for IDEXX Laboratories Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
IDEXX Laboratories Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
IDEXX Laboratories Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.84, ATR14 : 21.04, CCI20 : -85.56, Chaikin Money Flow : -0.13, MACD : -43.91, Money Flow Index : 17.48, ROC : -19.01, RSI : 29.34, STOCH (14,3) : 22.54, STOCH RSI : 1.00, UO : 35.97, Williams %R : -77.46), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of IDEXX Laboratories Inc. in the last 12-months were: Brian P. Mckeon (Option Excercise at a value of $3 189 519), Brian P. Mckeon (Sold 45 535 shares of value $28 485 272 ), Bruce L. Claflin (Option Excercise at a value of $307 898), Daniel M. Junius (Option Excercise at a value of $416 670), Daniel M. Junius (Sold 4 902 shares of value $2 981 273 ), Giovani Twigge (Option Excercise at a value of $7 556 014), Giovani Twigge (Sold 40 590 shares of value $28 341 797 ), James F. Polewaczyk (Option Excercise at a value of $678 500), James F. Polewaczyk (Sold 14 595 shares of value $8 527 691 ), Jonathan J. Mazelsky (Option Excercise at a value of $0), Jonathan J. Mazelsky (Sold 6 000 shares of value $4 051 262 ), Jonathan W. Ayers (Option Excercise at a value of $2 652 567), Jonathan W. Ayers (Sold 32 342 shares of value $17 657 279 ), Kathy V. Turner (Option Excercise at a value of $793 175), Kathy V. Turner (Sold 18 852 shares of value $11 033 724 ), M. Anne Szostak (Sold 2 400 shares of value $1 649 540 ), Michael J. Lane (Option Excercise at a value of $802 037), Michael J. Lane (Sold 6 494 shares of value $4 491 536 ), Nimrata Hunt (Option Excercise at a value of $174 085), Nimrata Hunt (Sold 538 shares of value $378 214 ), Sharon E. Underberg (Option Excercise at a value of $99 952)
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.